The Compounded GLP-1 Industry: Regulation, Risks, and Future Outlook

How Compounded GLP-1 Medications Came Into the Spotlight

Compounding — the preparation of customized medications by a pharmacist or outsourcing facility — has existed for decades. Compounded GLP-1 medications became widely discussed starting in 2022 and 2023, when FDA-approved GLP-1 drugs were in shortage. During a documented shortage, federal law allows compounding pharmacies and outsourcing facilities to prepare medications that are otherwise available only as FDA-approved products.

As demand for GLP-1 medications grew faster than the supply of brand-name products, compounded versions — primarily compounded semaglutide and, later, compounded tirzepatide — became available through telehealth platforms and compounding pharmacies across the United States.

The Two Regulatory Frameworks: 503A and 503B

Federal law recognizes two categories of compounders:

• Section 503A pharmacies are traditional, state-licensed compounding pharmacies. They compound medications based on individual prescriptions for specific patients. They are primarily regulated by state boards of pharmacy.
• Section 503B outsourcing facilities are FDA-registered facilities that compound medications on a larger scale. They are subject to current good manufacturing practice (cGMP) requirements and more direct FDA oversight.

Neither category means the compounded medication is FDA-approved. Compounded medications do not go through the FDA's drug approval process for safety, effectiveness, or quality. The distinction between 503A and 503B is about the regulatory framework under which a facility operates, not a quality certification for individual products.

What Happens When a Drug Shortage Ends

The availability of compounded versions of a drug is tied to the FDA's shortage list. When the FDA determines that a shortage has been resolved, compounding pharmacies and outsourcing facilities generally must stop preparing compounded versions of that drug.

This process has already affected compounded GLP-1 medications. In late 2024 and 2025, as the FDA determined that certain doses of semaglutide were no longer in shortage, the agency notified compounders that they would need to wind down production of those specific products. This created a transition period during which some patients on compounded semaglutide were switched to FDA-approved products or other treatment plans.

The key takeaway: compounded availability is not permanent. It depends on shortage status, which can change at any time based on FDA assessments of supply and demand.

Quality and Safety Considerations

Because compounded medications are not FDA-approved, their quality depends on the practices of the specific compounding facility. Considerations include:

• Ingredient sourcing: Compounded GLP-1 products typically use the active pharmaceutical ingredient (API), not the proprietary formulation used in brand-name products. The quality and purity of the API can vary by supplier.
• Sterility and formulation: Injectable compounded products must be prepared under sterile conditions. Outsourcing facilities registered under 503B are subject to cGMP requirements, while 503A pharmacies are primarily overseen by state boards.
• Concentration and labeling: Compounded products may be supplied in different concentrations or container types than brand-name products. It is essential to confirm the concentration, dosing units, and administration instructions with the prescribing clinician and dispensing pharmacy.
• Salts and forms: In 2025, the FDA clarified that compounded products using non-pharmaceutical-grade forms — such as products using forms of semaglutide not consistent with the approved drug — should not be dispensed. This is an evolving area.

The Role of Telehealth

Many compounded GLP-1 medications are prescribed through telehealth platforms that connect patients with prescribing clinicians and partner with compounding pharmacies. The telehealth model has made access faster and more convenient, but it also means the patient may not have a long-standing relationship with the prescribing clinician.

When evaluating any telehealth provider, it is reasonable to ask which compounding pharmacy prepares the medication, whether the pharmacy is licensed in your state, what the concentration and dosing schedule are, and what happens if the compounded version becomes unavailable.

Future Outlook

Several factors will shape the compounded GLP-1 landscape in the coming years:

• Shortage resolution: As brand-name manufacturers increase production, the FDA may remove more doses from the shortage list, reducing the legal basis for compounding those products.
• New FDA-approved products: Additional GLP-1 and multi-agonist medications are in development and approval pipelines. As more approved options become available, the gap that compounding fills may narrow.
• Regulatory enforcement: The FDA has signaled continued scrutiny of compounded GLP-1 products, particularly around ingredient quality, formulation, and marketing claims. Enforcement actions may affect which products remain available.
• Oral formulations: Research into oral GLP-1 medications could shift the market away from injectable compounded products if approved oral options become widely available.
• State-level regulation: State boards of pharmacy may implement additional requirements for compounding GLP-1 products, adding another layer of variability.

What This Means for Patients

If you are currently using or considering a compounded GLP-1 medication, the most practical steps are:

1. Know which pharmacy prepares your medication and verify that it is licensed in your state.
2. Keep records of your concentration, dose, and schedule so that any transition to a different product can be handled safely.
3. Ask your prescriber what happens if the compounded version becomes unavailable — whether a transition to an FDA-approved product or an alternative plan is available.
4. Report any concerns about product quality, side effects, or labeling to your healthcare provider and, if appropriate, to the FDA's MedWatch program.

The Bottom Line

The compounded GLP-1 industry exists because of a specific set of regulatory circumstances — primarily drug shortages. As those circumstances change, availability will change too. Understanding the regulatory framework, the quality considerations, and the factors that may affect future access can help you make informed decisions in conversation with your healthcare team.

---

This article is for educational purposes only and is not medical advice. Compounded medications are not FDA-approved. Always consult a licensed healthcare professional before starting, changing, or stopping any medication.